IviGene Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
IviGene General Information
Description
Owner and operator of a biotechnology company intended to facilitate genetic research for the study of antigens. The company's services focus on incorporating an In Vivo Induced Antigen Technology which uses antibodies present in the blood of patients infected with or recently recovered from infection with a particular pathogen and help generate and screen antibodies that serve as probes to screen a genomic expression library of the pathogen in order to identify proteins that are specifically expressed during an actual human infection, enabling medical researchers to develop and innovate drugs using antibodies for treating and curing chronic diseases and for vaccine diagnostic and pharmaceutical development.
Contact Information
Website
www.ivigene.comCorporate Office
- 12085 Research Drive
- Alachua, FL 32615
- United States
Corporate Office
- 12085 Research Drive
- Alachua, FL 32615
- United States
IviGene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 20-Nov-2006 | 000 | Completed | Startup | ||
| 2. Corporate | 12-Mar-2001 | 000 | 000 | 000 | Completed | Startup |
| 1. Accelerator/Incubator | Completed | Startup |
IviGene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
IviGene Patents
IviGene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20100072196-A1 | Controlled venting food package | Inactive | 24-Sep-2008 | 0000000000 | 0 |
| AU-2003225678-A1 | Identification of microbial polynucleotides expressed during infection of a host | Inactive | 06-Mar-2002 | 00000000000 | |
| AU-2003230557-A1 | In situ induced antigen technology (isiat) for identification of polynucleotides expressed during infection or colonization | Inactive | 22-Feb-2002 | 00000000000 | |
| AU-2003230557-A8 | In situ induced antigen technology (isiat) for identification of polynucleotides expressed during infection or colonization | Inactive | 22-Feb-2002 | 00000000000 | |
| ES-2184659-T1 | Microbial polinucleotides expressed during infection of a hospeding organism. | Pending | 06-Aug-1999 | C12N15/1072 |
IviGene Executive Team (3)
| Name | Title | Board Seat |
|---|---|---|
| Martin Handfield Ph.D | Co-Founder |
IviGene Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| UF Innovate Ventures | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |
| Xtl Biopharmaceuticals | Corporation | Minority | 000 0000 | 000000 0 |
IviGene FAQs
-
When was IviGene founded?
IviGene was founded in 2000.
-
Who is the founder of IviGene?
Ann Perogulske-Fox, Jeffrey Hillman Ph.D, and Martin Handfield Ph.D are the founders of IviGene.
-
Where is IviGene headquartered?
IviGene is headquartered in Alachua, FL.
-
What industry is IviGene in?
IviGene’s primary industry is Biotechnology.
-
Is IviGene a private or public company?
IviGene is a Private company.
-
What is IviGene’s current revenue?
The current revenue for IviGene is 00000.
-
How much funding has IviGene raised over time?
IviGene has raised $1M.
-
Who are IviGene’s investors?
UF Innovate Ventures and Xtl Biopharmaceuticals have invested in IviGene.
-
When was IviGene acquired?
IviGene was acquired on 20-Nov-2006.
-
Who acquired IviGene?
IviGene was acquired by Oragenics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
